Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
50%(2 trials)

Phase Distribution

Ph not_applicable
1
14%
Ph phase_3
4
57%
Ph phase_1
1
14%
Ph phase_2
1
14%

Phase Distribution

1

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
4(57.1%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(4)
Terminated(2)
Other(1)

Detailed Status

Completed4
Withdrawn2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 21 (14.3%)
Phase 34 (57.1%)
N/A1 (14.3%)

Trials by Status

withdrawn229%
completed457%
unknown114%

Recent Activity

0 active trials
Showing 5 of 7
withdrawnphase_3

Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit

NCT04853927
withdrawnphase_3

Proxalutamide Treatment for COVID-19 Female Outpatients

NCT04853134
completednot_applicable

Anti-Androgen Treatment for COVID-19

NCT04446429
completedphase_3

The South Proxa-Rescue AndroCoV Trial Against COVID-19

NCT05126628
unknownphase_2

Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy（ADT）for High Risk Prostate Cancer

NCT05076851
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04853927Phase 3

Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit

Withdrawn
NCT04853134Phase 3

Proxalutamide Treatment for COVID-19 Female Outpatients

Withdrawn
NCT04446429Not Applicable

Anti-Androgen Treatment for COVID-19

Completed
NCT05126628Phase 3

The South Proxa-Rescue AndroCoV Trial Against COVID-19

Completed
NCT05076851Phase 2

Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy（ADT）for High Risk Prostate Cancer

Unknown
NCT04103853Phase 1

Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer

Completed
NCT04728802Phase 3

Proxalutamide Treatment for Hospitalized COVID-19 Patients

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7